Promising Drugs in Boehringer-Ingelheim Pipeline
| Compound* | Clinical phase | Indication | Therapeutic principle | Mode of action |
|---|---|---|---|---|
| Olodaterol | Submitted | Chronic obstructive pulmonary Disease (COPD) | Long-acting beta-agonist | Bronchodilation |
| Tiotropium | Submitted | Cystic fibrosis (CF) | Bronchodilatator | Long Acting Muscarinic Antagonist |
| Afatinib | Phase III | Breast cancer | Signal transduction inhibition | Novel irreversible ErbB Family blocker |
| Afatinib | Phase III | Head and neck cancer | Signal transduction inhibition | Novel irreversible ErbB Family blocker |
| Deleobuvir (BI 207127) |
Phase III | Hepatitis C | Direct acting antiviral small molecule | Oral NS5B RNA-dependent polymerase inhibitor |
| Empagliflozin | Phase III | Diabetes mellitus type II |
SGLT-2-inhibitor | Inhibition of glucose transporter-2 |
| Faldaprevir (BI 201335) |
Phase III | Hepatitis C | Direct acting antiviral small molecule | Oral HCV NS3/4A protease inhibitor |
| Nintedanib | Phase III | Non-small cell lung cancer (NSCLC) | Angiogenesis inhibition | Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR |
| Nintedanib | Phase III | Ovarian cancer | Angiogenesis inhibition | Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR |
| Nintedanib | Phase III | Idiopathic pulmonary fibrosis (IPF) | Anti-fibrotic kinase inhibition | Anti-fibrotic kinase inhibitor |
| Tiotropium | Phase III | Asthma | Bronchodilatator | Long Acting Muscarinic Antagonist |
| Volasertib | Phase III | Various cancer types | Cell-cycle kinase inhibition | PLK-1 antagonist |
* These are investigational agents; their safety and efficacy have not yet been established.
Status: April 2013
Successful Products from our Boehringer-Ingelheim Research & Development
| Product name | First launch | Active ingredient | Indication |
|---|---|---|---|
| Gilotrif™ | 2013 | Afatinib | Non-small cell lung cancer (NSCLC) |
| Trajenta® | 2011 | Linagliptin | Diabetes mellitus type II |
| Pradaxa® | 2010 2008 |
Dabigatran etexilate | Stroke prevention in atrial fibrillationPrevention of venous thromboembolic events (VTE) in adults |
| Spiriva® Respimat Soft Mist™ InhalerSpiriva® |
2007 2002 |
Tiotropium | COPD |
| Micardis® | 1998 | Telmisartan | Essential hypertension |
| Sifrol® / Mirapex® /Mirapexin® | 20061997 | Pramipexole | Restless legs syndrome (RLS) Parkinson’s disease (PD) |
| Viramune® | 1996 | Nevirapine | HIV/AIDS |
Oncology Websites
No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
